| Submission | Oct. 29, 2024 |
| Submission [Line Items] | |
| Central Index Key | 0001157601 |
| Registrant Name | Madrigal Pharmaceuticals, Inc. |
| Form Type | S-8 |
| Submission Type | S-8 |
| Fee Exhibit Type | EX-FILING FEES |
| Offerings - Offering: 1 | Oct. 29, 2024 USD ($) shares |
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, $0.0001 par value per share |
| Amount Registered | shares | 750,000 |
| Proposed Maximum Offering Price per Unit | 203.41 |
| Maximum Aggregate Offering Price | $ 152,557,500 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 23,356.56 |
| Offering Note | (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (2) Represents an increase of 750,000 shares of Common Stock available for issuance under the Plan, as approved on June 25, 2024. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $203.41, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on October 24, 2024 (such date being within five business days of the date that this Registration Statement was filed with the Commission). |
| Fees Summary | Oct. 29, 2024 USD ($) |
| Fees Summary [Line Items] | |
| Total Offering | $ 152,557,500 |
| Total Fee Amount | 23,356.56 |
| Total Offset Amount | 0 |
| Net Fee | $ 23,356.56 |
